Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
101. |
ECCT/23/04/05 | BiMVaC01 A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults. |
Principal Investigator(s) 1. NDUNGU FRANCIS 2. Said Jongo Site(s) in Kenya KEMRI-CGMRC Kilifi |
06-07-2023 |
View |
102. |
ECCT/23/04/03 | ACTIV-2d/A5407 A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 |
Principal Investigator(s) 1. Prof Abraham Mosigisi Siika Site(s) in Kenya 1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 2. Victoria Biomedical Research Institute, (Kisumu county) 3. Kenyatta National Hospital (Nairobi City county) 4. KEMRI CCR – BUTERE SITE (Kakamega county) 5. Kenya Medical Research Institute/Walter Reed Project (Kericho county) 6. KEMRI – AHERO Clinical Trials Units (Kisumu county) |
14-06-2023 |
View |
103. |
ECCT/23/03/06 | PDMC-II Dihydroartemisinin-piperaquine and azithromycin for the post-discharge management of children with severe anaemia in Malawi, Kenya and Uganda; A, multicentre, parallel-group, two-arm, randomised, double-blind superiority trial. |
Principal Investigator(s) 1. Simon Kariuki 2. Titus Kwambai Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital |
16-08-2023 |
View |
104. |
ECCT/23/03/04 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) |
31-07-2023 |
View |
105. |
ECCT/23/03/05 | SKY-06 A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER |
Principal Investigator(s) 1. Dr Primus Ochieng Site(s) in Kenya 1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
11-08-2023 |
View |
106. |
ECCT/23/05/07 | LATA Long-Acting Treatment in Adolescents (LATA) A randomised open-label 2-arm 96 week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. |
11-09-2023 |
View |
107. |
ECCT/23/01/03 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Githanga Githanga Nyokabi Site(s) in Kenya 1. Gertrude\'s Children Hospital (Nairobi City county) 2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county) 4. Kombewa CRC (Kisumu county) |
19-06-2023 |
View |
108. |
ECCT/23/03/03 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/USAMRD (Kericho county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) |
12-05-2023 |
View |
109. |
ECCT/23/01/08 | SKY-06 A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya International Cancer Institute |
28-05-2023 |
View |
110. |
ECCT/23/03/02 | Sunrise-3 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 |
Principal Investigator(s) 1. Dr. Paul Yonga 2. Dr John Kinuthia 3. DR LUCAS OTIENO TINA Site(s) in Kenya 1. Fountain Projects and Research Office, Clinical Research Centre (FOPRO-CRC) (Kisumu county) 2. KENYATTA NATIONAL HOSPITAL (Nairobi City county) 3. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
09-08-2023 |
View |